Edgewise Therapeutics, Inc. (EWTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Boulder, CO, 미국. 현재 CEO는 Kevin Koch.
EWTX 을(를) 보유 IPO 날짜 2021-03-26, 117 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $3.56B.
Edgewise Therapeutics, Inc. is a biopharmaceutical company focused on developing small molecule therapies for musculoskeletal diseases, particularly rare genetic muscle disorders. The company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy, and has completed Phase 1 clinical trials. Edgewise is building a pipeline of precision medicine candidates that target key muscle proteins and modulators to treat genetically defined muscle disorders. Founded in 2017 and headquartered in Boulder, Colorado, the company is advancing innovative therapeutic approaches for patients with serious muscle-wasting conditions.
